Bank of America Corp DE increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 10.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 362,952 shares of the specialty pharmaceutical company’s stock after buying an additional 35,069 shares during the period. Bank of America Corp DE owned 0.72% of Supernus Pharmaceuticals worth $11,361,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently made changes to their positions in SUPN. Columbus Circle Investors increased its position in shares of Supernus Pharmaceuticals by 3.7% in the first quarter. Columbus Circle Investors now owns 58,035 shares of the specialty pharmaceutical company’s stock valued at $1,816,000 after buying an additional 2,062 shares during the period. Rice Hall James & Associates LLC increased its position in shares of Supernus Pharmaceuticals by 1.1% in the first quarter. Rice Hall James & Associates LLC now owns 1,093,402 shares of the specialty pharmaceutical company’s stock valued at $34,223,000 after buying an additional 11,662 shares during the period. Capital Impact Advisors LLC acquired a new position in shares of Supernus Pharmaceuticals during the first quarter valued at $1,263,000. Legato Capital Management LLC increased its position in shares of Supernus Pharmaceuticals by 3,030.0% in the first quarter. Legato Capital Management LLC now owns 67,577 shares of the specialty pharmaceutical company’s stock valued at $2,159,000 after buying an additional 65,418 shares during the period. Finally, Louisiana State Employees Retirement System increased its position in shares of Supernus Pharmaceuticals by 2.5% in the first quarter. Louisiana State Employees Retirement System now owns 20,400 shares of the specialty pharmaceutical company’s stock valued at $639,000 after buying an additional 500 shares during the period. Institutional investors and hedge funds own 90.97% of the company’s stock.
Supernus Pharmaceuticals, Inc. (SUPN) opened at 41.00 on Friday. The company has a 50-day moving average price of $42.17 and a 200-day moving average price of $32.99. The firm has a market capitalization of $2.06 billion, a PE ratio of 22.05 and a beta of 1.34. Supernus Pharmaceuticals, Inc. has a 12-month low of $17.25 and a 12-month high of $44.95.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.22 by $0.03. The business had revenue of $57.58 million for the quarter, compared to the consensus estimate of $57.91 million. Supernus Pharmaceuticals had a return on equity of 31.79% and a net margin of 42.46%. On average, analysts predict that Supernus Pharmaceuticals, Inc. will post $1.01 earnings per share for the current year.
A number of analysts have commented on SUPN shares. Zacks Investment Research raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price objective for the company in a report on Thursday, July 13th. BidaskClub upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. Jefferies Group LLC set a $35.00 price target on Supernus Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 10th. Stifel Nicolaus reiterated a “buy” rating and set a $47.00 price objective (up from $36.00) on shares of Supernus Pharmaceuticals in a research note on Tuesday, July 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $31.00 price objective on shares of Supernus Pharmaceuticals in a research note on Friday, April 7th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $46.14.
In other news, VP Padmanabh P. Bhatt sold 3,735 shares of the firm’s stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $44.90, for a total transaction of $167,701.50. Following the completion of the transaction, the vice president now directly owns 21,209 shares of the company’s stock, valued at approximately $952,284.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 2,500 shares of the firm’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $35.90, for a total transaction of $89,750.00. Following the transaction, the vice president now directly owns 37,500 shares of the company’s stock, valued at $1,346,250. The disclosure for this sale can be found here. Insiders have sold a total of 24,291 shares of company stock valued at $962,766 over the last ninety days. 6.70% of the stock is owned by insiders.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
